A recent study published in Nature Aging has provided striking evidence of the connections between amyloid deposits found in the brain and those in the bone marrow, particularly in aged mice. Conducted by a research team at The Johns Hopkins University School of Medicine, this research represents a pivotal step in understanding the broader implications of amyloid protein behavior outside of traditional neurological contexts.
Study Overview
The key finding of this study suggests that amyloid beta protein, a hallmark of Alzheimer's disease (AD), exhibits a unique accumulation in the bone marrow of aging mice. Unlike the classic large, dense plaques associated with AD in the brain, the amyloid deposits in bone marrow appear in a different form. Dr. Mei Wan, a contributing author of the study, highlights the importance of this discovery: “While brain amyloid has been extensively studied for its role in memory loss and neurodegeneration, far less is known about amyloid elsewhere in the body.”
Linking Bones and Alzheimer's
The results of the study suggest a potential relationship between amyloid buildup and two age-related conditions: AD and osteoporosis. Osteoporosis is defined as a bone disease marked by low bone mineral density, which increases the risk of fractures. The presence of amyloid deposits in both the brain and the bones may indicate shared biological processes that contribute to these conditions.
| Condition | Characteristics | Link to Amyloid |
|---|---|---|
| Alzheimer's Disease | Characterized by memory loss and cognitive decline. | Excessive amyloid plaques in the brain. |
| Osteoporosis | Marked by low bone density and increased fracture risk. | Amyloid deposits impair bone health. |
Mechanisms of Amyloid Buildup
The buildup of amyloid in bone marrow is attributed to specific fat cells known as bone marrow adipocytes (BMAds), which release a protein called SAP/PTX2. As age progresses, these proteins are believed to trigger the accumulation of amyloid deposits, subsequently impairing osteoblast (bone-building) function and activating osteoclast (bone-resorbing) activity, ultimately contributing to bone loss.
Previous studies demonstrated that targeting these senescent BMAds or inhibiting the SAP/PTX2 protein can significantly reduce amyloid levels and restore bone health.
Experimental Design
In the study, both male and female mice aged between 4 to 24 months were evaluated in a controlled environment with consistent access to food and water and were exposed to a regular light-dark cycle. A concentration of CPHPC (also known as Miridesap) was introduced into the drinking water of the older mice to investigate its effects on age-related bone loss.
| Age Group (Months) | Experimental Treatment | Outcome |
|---|---|---|
| 4-24 | 5mg/ml CPHPC | Reversal of bone deterioration and depletion of SAP/PTX2. |
| Control Group | Water without CPHPC | No significant change detected. |
Implications of Findings
“Our findings uncover a new connection between bone loss and dementia risk and may open the door to new research on how protecting bone health could also help protect brain function.” – Dr. Mei Wan, Lead Researcher
The results of this research suggest new therapeutic targets for conditions such as osteoporosis, especially those associated with Alzheimer's. By focusing on the elimination of senescent adipocytes and amyloid-promoting proteins, future treatments may positively affect both bone and brain health.
Conclusions
This novel insight into the connections between amyloid buildup in both the brain and bone marrow highlights the need for further investigations into shared biological mechanisms. Recognizing the role of amyloid in both Alzheimer’s disease and osteoporosis could revolutionize the approach to treating these age-related conditions.
For more comprehensive details, refer to the original study: Kumar, S. et al. (2025). Serum amyloid P secreted by bone marrow adipocytes drives skeletal amyloidosis. Nature Aging.
Discussion